BioHarvest Sciences Inc. reported its financial results for the first quarter ended March 31, 2025. The company achieved revenue of $7.9 million, representing a 47% increase year-over-year, which exceeded management's guidance.
The strong revenue performance was complemented by continued gross margin expansion. Gross margins improved to 58.5% in Q1 2025, reflecting ongoing operational efficiencies and increased manufacturing scale.
These results indicate sustained momentum in BioHarvest's business, driven by its VINIA product line and the developing CDMO services. The company continues to execute on its growth strategy, aiming for adjusted EBITDA breakeven in the second half of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.